Dr. Udell is a Cardiologist and Clinician-Scientist at Women’s College Hospital and the Peter Munk Cardiac Centre at the University Health Network; an Adjunct Scientist at ICES (the Institute for Clinical Evaluative Sciences); Affiliate Scientist at AHRC (Applied Health Research Centre), Li Ka Shing Knowledge Institute, St. Michael’s Hospital; and an Associate Professor of Medicine at the University of Toronto. His research group conducts large observational studies and clinical trials testing strategies and treatments for primary and secondary prevention of ischemic heart disease and heart failure. As a co-PI, national lead investigator, or steering committee member, Dr. Udell has studied the cardioprotective effects of influenza vaccine, SGLT2 inhibitors, angiotensin receptor-neprilysin inhibitors, mineralocorticoid antagonists, antithrombotic and lipid lower therapies in various high risk populations. Currently he is the co-PI of CHOICES, a Canadian Institutes for Health Research (CIHR)-funded Strategy for Patient-Oriented Research (SPOR) Innovative Clinical Trial, which is testing a provincial report card strategy on primary care performance measures for cholesterol management. He is also a co-lead of the international, multicentre EMPACT-MI trial, testing the early use of an SGLT2 inhibitor in high-risk heart attack patients to reduce the risk of premature death and the onset of heart failure. Dr. Udell has also contributed to the writing committee of national guidelines, including the 2018 Canadian Cardiovascular Society Antiplatelet Therapy Guideline Update, 2018 Diabetes Canada Clinical Practice Guideline, and 2021 Heart and Stroke Foundation Canadian Stroke Best Practice Recommendation Guideline.